BIOGEN INC. - 10-Q Filing

Biogen Inc. reports Q3 2026 financial results including revenue breakdowns by product and integration costs related to Apellis Pharmaceuticals.

SEC EDGAR ·

Tickers: $BIIB

Read the full article at SEC EDGAR

More Regulatory news